Marketing: Page 76
-
Deep Dive
How 21st Century Cures could change communications between biopharma, providers, & patients
Some are worried that expanding regulations around biopharma communications could lead to a "wild West" situation. But experts consider the proposed changes "modest."
By Nicole Gray • June 11, 2015 -
Pennsylvania's Melior wins a Parkinson's patent
The patent covers L-dopa-associated dyskinesia.
By Nicole Gray • June 11, 2015 -
Explore the Trendlineâž”
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.
By BioPharma Dive staff -
PCSK9 anti-cholesterol drug prices: How much is too much?
Prime Therapeutics, a PBM, has warned that PCSK9 inhibitors could cost the healthcare system up to $23.3 billion per year.
By Nicole Gray • June 10, 2015 -
Report: Many heart attack patients neglect to take their meds afterwards
According to researchers from Duke University.
By Nicole Gray • June 4, 2015 -
PillPack just got a $50 million infusion—could it become the Amazon of pharmacies?
The startup is looking to disrupt the pharmacy inustry with novel drug-packaging ideas.
By Nicole Gray • June 4, 2015 -
Express Scripts pushes 'pay-for-performance' drug policy in latest challenge to pharma
Under a policy known as 'indication-based pricing,' insurers would pay different amounts based on therapeutic outcomes.
By Nicole Gray • May 28, 2015 -
Report: Greece owes pharma companies more than $1.2 billion in debts
Greek hospitals and the EOPYY, the state-run insurer, have not paid pharma debts since December 2014.
By Nicole Gray • May 28, 2015 -
Disadvantage, Amgen? Dosing could be deciding factor in PCSK9 marketing battle
That's good news for Sanofi/Regeneron's Praluent.
By Nicole Gray • May 27, 2015 -
Deep Dive
ProPublica opens up the Advair vault, raises safety and marketing ethics questions
When does meeting an unmet medical need become promoting drug overutilization? It can be a fine line.
By Nicole Gray • May 22, 2015 -
Top FDA official: Listing detailed drug risks in pharma TV ads a 'waste of time'
The FDA's office of hematology and oncology products chief isn't mincing words.
By Sy Mukherjee • May 20, 2015 -
Deep Dive
Why biosimilars may not be the huge cost-saver people hope
A DRG analyst cautions biosimilar optimists to take the long view in terms of cost-savings.
By Nicole Gray • May 20, 2015 -
WHO plays hardball with Novartis & Roche, favors cheaper Avastin over Lucentis
The global health agency rejected Novartis' request to add Lucentis (ranibizumab) to the List of Essential Medicines to treat AMD, a leading cause of blindness.
By Nicole Gray • May 19, 2015 -
Why are analysts still optimistic about Orexigen's stock after the Contrave imbroglio?
The diet drug maker's stock plummeted 27% in two days. But most surveyed analysts are still calling it a "buy."
By Nicole Gray • May 15, 2015 -
MannKind: Marketing glitches, delays explain slow Afrezza uptake
Uptake of the first approved inhaled insulin has been stifled by safety concerns and reimbursement challenges.
By Nicole Gray • May 13, 2015 -
Deep Dive
Analysts answer: How long will it take the first Copaxone generics to gain market share?
We spoke with two DRG analysts about how the first generic substitutable version of Copaxone will change treatment of multiple sclerosis over the next five to 10 years.
By Nicole Gray • May 13, 2015 -
FDA
FDA staff raises red flags over new Vertex cystic fibrosis med's cost
Agency staff is questioning whether Orkambi is worth the price.
By Nicole Gray • May 11, 2015 -
In challenge to pricey Gilead meds, WHO adds hep C drugs to 'essentials' list
This is the first time in two years that the WHO's Model List of Essential Medicines has been updated.
By Nicole Gray • May 11, 2015 -
Study: Measles vax may protect against other infections
The protective effect can last for up to three years, according to researchers.
By Nicole Gray • May 8, 2015 -
Mark your calendars: FDA will hold public meeting on off-label use this summer
A coalition of pharma companies is advocating for looser rules around off-label advertising.
By Nicole Gray • May 8, 2015 -
Glaxo hoping for the best, prepping for the worst on Advair generics
The company says generics of the asthma and COPD best-seller are more than a year away, but has factored generics into its five-year forecast.
By Nicole Gray • May 7, 2015 -
IMS: Global cancer drug spending soared past $100 billion in 2014
And the U.S. accounted for more than 40% of the spending.
By Nicole Gray • May 6, 2015 -
The new Medicare Part D drug spending report only tells part of the story
According to newly released CMS data, providing Nexium to seniors cost Medicare $2.5 billion in 2013—but that doesn't factor in rebates.
By Nicole Gray • May 5, 2015 -
Viagra bucks global slowdown trend in China, sales soar 47%
Overall global sales of the Pfizer mainstay plunged 24%.
By Nicole Gray • May 4, 2015 -
Gilead dazzles, profits double in Q1 on strong hep C sales
The biotech's shares jumped about 4% in Friday morning trading on the news.
By Nicole Gray • May 1, 2015 -
Deep DiveThe 10 brand name drugs that cost Medicare Part D the most money in 2013
Generics cost the insurance program for the elderly the most money overall. But among branded meds, Part D spent the most money on drugs like Nexium and Advair.
By Sy Mukherjee • April 30, 2015
Previous
